Chief Investigator: 
Dr Paul Mulholland




Full Title: A Phase II, Open Label, Randomised Study of Ipilimumab with Temozolomide versus Temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma

Sponsor: University of Oxford

Trial Design:

This is an unblinded, open labelled stratified randomised Phase II multicentre clinical trial (CTIMP). Patients with newly diagnosed de-novo glioblastoma following surgery or biopsy and radical radiotherapy with concomitant temozolomide will be recruited from 5-7 sites in the UK.




Target:120 Patients

Primary Objective:

To evaluate whether the addition of ipilimumab to the current standard of care following surgery and chemoradiotherapy will improve survival in patients with newly diagnosed glioblastoma

Secondary Objective:

To evaluate the safety and tolerability of ipilimumab plus temozolomide


Target Opening to Recruitment: 07 December2018

Funding: The study is funded by Bristol Myers-Squibb and The National Brain Appeal.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.